Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACTS John J. Trizzino Chief Executive Officer Vicki Morgan VP, Business Development ADDRESS 1344 Summer Street, Suite 412 Halifax, Nova Scotia B3H 0A8 CANADA TELEPHONE 902-492-1819 FAX 902-492-0888 EMAIL jtrizzino@imvaccie.com vmorgan@imvaccine.com YEAR FOUNDED 2000 Immunovaccine Inc. www.imvaccine.com FINANCIAL SUMMARY Shares outstanding: 63.5M Recent Market Cap: $17.8M Recent share price: $0.28 52 Week Range: $0.28 – $0.60 Average Daily Volume: 35,500 Cash & Other Cash Resources (31/12/11): $6.2M COMPANY PROFILE Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The Company’s DepoVax platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I clinical trials and has demonstrated both safety and immunogenicity potential. Immunovaccine is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the Company’s delivery technology platform to develop vaccines for livestock. MANAGEMENT John J. Trizzino, CEO Vicki Morgan, VP, Business Development Kimberly Stephens, CFO Marc Mansour, Ph.D., CSO Board of Directors Albert Scardino, Chairman, Communications Strategist, Pulitzer Prize Recipient William Cochrane, MD, 2010 Inductee Canadian Medical Hall of Fame Wade Dawe, CEO of Brigus Gold James Hall, CA, Sr.VP of Investments GrowthWorks Stephanie Léouzon, Senior Advisor to Torreya Partners Wayne Pisano, Former President and CEO of Sanofi Pasteur Brad Thompson, CEO of Oncolytics t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Roel Q. J Schaapveld, PhD, MBA Chief Executive Officer ADDRESS Hugo R. Kruyt building Padualaan 8 3584 CH Utrecht The Netherlands TELEPHONE +31 30 253 2386 FAX +31 30 253 9176 EMAIL schaapveld @interna-technologies.com YEAR FOUNDED December 2006 InteRNA Technologies B.V. www.interna-technologies.com FINANCIAL SUMMARY Investors: • Aglaia Oncology Fund • PPM Oost COMPANY PROFILE InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel breakthrough cancer therapies based on the unique functions of its proprietary miRNAs. InteRNA’s drug development programs aim at developing miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes that are known to play a role in cancer initiation, progression and metastasis. InteRNA identified the function of multiple miRNAs in a number of cancer indications through functional screens, using its proprietary lentiviral-based miRNA expression library, which is the largest currently available. With the Company’s proprietary miRNA expression database (generated through deep sequencing) and additional technologies (like RNAseq, bioinformatics, in vivo models) in place to identify the downstream regulated proteins for each miRNA drug candidate, the Company is well equipped to move its novel drug candidates with their biomarkers quickly towards the clinic. MANAGEMENT Roel Q.J. Schaapveld, PhD, MBA, Chief Executive Officer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63: CONTACTS Kevin FitzGerald Chief Ope
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?